🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  2. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  3. Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Spontaneous lobar ICH

    phase 3 small molecule active

    1 trial

  4. Sodio Cloruro Fresenius Kabi Italia 0,9%, solvente per uso parenterale, Samyr placebo (saline solution), SAMYR 400 mg/5ml polvere e solvente per soluzione iniettabile

    Mylan dura GmbH

    Major Depression Disorders

    phase 3 small molecule active

    1 trial

  5. Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3

    Travere Therapeutics

    Focal segmental glomerulosclerosis (FSGS)

    phase 3 small molecule active

    1 trial

  6. Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)

    AstraZeneca AB

    Inadequately Controlled Asthma

    phase 3 small molecule active

    1 trial

  7. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  8. TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  9. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  10. TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets

    AstraZeneca

    HR+ / HER2- advanced breast cancer

    phase 3 small molecule active

    1 trial

  11. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Roche Registration Limited

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  12. TV-46000

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  13. Tablet placebo for aficamten 5mg tablet, Aficamten

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  14. Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)

    United Therapeutics Europe Ltd

    Critical Illness

    phase 3 other active

    2 trials

  15. Tecentriq 1 200 mg concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  16. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Roche Registration Limited

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  17. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  18. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  19. Trazimera 420 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion, VINORELBINE ARROW 10 mg/ml, solution à diluer pour perfusion, TherO2-01S22, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Placebo syrup, Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  20. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  21. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  22. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  23. Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection

    ViiV Healthcare BV

    HIV Infections

    phase 3 small molecule active

    1 trial

  24. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources